AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04049916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primaquine Diphosphate
Description: Extemporaneous preparation of 1mg/mL primaquine phosphate solution, from tablets containing 30mg primaquine (A-PQ 30®, ACE pharmaceuticals, NL) dissolved in 30mL water with a non-interacting fruit-flavoured syrup. Solution will be given at 0.25mg/kg.
Study NCT02868541 — intervention group
Intervention type: OTHER
Intervention: Naso pharyngeal swab
Description: Naso pharyngeal swab
Study NCT00810173 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: phone call support
Description: The intervention group received a phone call support for 6 weeks to incentive to increase the number of steps/day.
Study NCT05571267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimura
Description: Zimura 2 mg, administered by intravitreal injection
Study NCT04207021 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental: Curcumin derivate
Description: two capsules per day, one capsule to be taken before breakfast and one before dinner for a period of 6 weeks.
Study NCT04207021 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: two capsules per day (containing no bioactive compound, only hydroxypropyl methylcellulose, gellan gum, pigment), one capsule to be taken before breakfast and one before dinner for a period of 6 weeks.
Study NCT05571267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin
Description: Avastin 1.25 mg, administered by intravitreal injection
Study NCT05571267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucentis
Description: Lucentis 0.5 mg, administered by intravitreal injection
Study NCT05571267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eylea
Description: Eylea 2 mg, administered by intravitreal injection
Study NCT02591212 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Green Dot
Description: Green Dot bystander intervention program (www.livethegreendot.com) seeks to empower potential bystanders (students) to actively engage their peers in violence prevention. Intensive bystander training involves interactive, skill development with role-play of bystander behaviors. This program focuses on building knowledge and skills related to interpersonal violence and being an active bystander. There is a structured curriculum for both introductory sessions and longer, skill-building sessions.
Study NCT02591212 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Wellness Initiatives for Student Empowerment
Description: Wellness training to be provided in modules by Student Wellness ambassadors (http://www.uky.edu/wise). The Student Wellness Ambassadors mission is to inform students on aspects of wellness such as alcohol, drugs, mental health, general well-being, and financial wellness in orer to promote safe and responsible lifestyle decisions. Intervention will address elements of student wellness including campus resources for health issues, AOD abuse prevention/harm reduction strategies, time management and study tips, stress management and reduction, and healthy coping strategies. Training may also provide information on academic resources, money management, and other elements of healthy adaptation to college life.
Study NCT03574311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose
Description: A single dose of drug or placebo is administered preoperatively to participants
Study NCT03574311 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Physiological saline
Description: Single infusion 100 ml physiological saline infusion preoperatively
Study NCT01699529 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Multi-electrode Radiofrequency (RF) Renal Denervation system
Description: The Medtronic Multi-electrode Radiofrequency Renal Denervation System is comprised of a single-use, disposable catheter and a reusable generator.
Study NCT01246362 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Given placebo
Study NCT01246362 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoricoxib
Description: Given etoricoxib 120mg 24 hours preoperatively and 120mg 2 hours preoperatively
Study NCT03476317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: Oral suspension 4 times daily (Day 1-14)
Study NCT03476317 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vancomycin
Description: Oral suspension 4 times daily (Day 1-14)
Study NCT03476317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neomycin
Description: Oral three times daily (Days 1-3)
Study NCT02466919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: H. pylori eradication therapy
Study NCT02466919 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: H. pylori eradication therapy
Study NCT02466919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Description: H. pylori eradication therapy
Study NCT03476317 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Neomycin
Description: Oral three times daily (Days 1-3)
Study NCT03476317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Description: Oral twice daily (Days 4-14)
Study NCT03476317 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ciprofloxacin
Description: Oral twice daily (Days 4-14)
Study NCT03476317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethylene Glycol 3350
Description: Dissolved in Gatorade on day 2
Study NCT03476317 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Polyethylene Glycol 3350
Description: Dissolved in Gatorade on day 2
Study NCT03476317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole
Description: Orally once daily (Day 1-14)
Study NCT04553224 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Clinical evaluations
Description: SCORAD and target SCORAD
Study NCT04553224 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Non-invasive instrumental measurements
Description: TEWL, cutaneous hydration, skin lipidic analysis, colorimetry, hydration index
Study NCT04553224 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Subject's evaluations
Description: PO-SCORAD, target PO-SCORAD and subject's questionnaire
Study NCT03417791 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT00353652 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Study#1: chlorthalidone (CTD), titrated dose
Description: Participants in study #1 will receive 3 months of chlorthalidone (12.5-25 mg/d) at the dose titrated to achieve 24-h ambulatory BP \< 130/80 mmHg
Study NCT02466919 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: H. pylori eradication therapy
Study NCT04165837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FB-101
Description: Part A - Single Ascending Dose study Part B - Multiple Ascending Dose study
Study NCT04165837 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Part A - Single Ascending Dose matching placebo study Part B - Multiple Ascending Dose matching placebo study
Study NCT03212729 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: ANTIMICROBIAL PHOTODYNAMIC THERAPY
Description: The aPDT was performed with 0.01% methylene blue and irradiated with low-level laser therapy (InGaAIP, 660 nm; 100 mW; 40 sec) with an optical fiber-coupled. Another irradiation (3 J; 30 sec; spot size of 3 mm2) was performed in the gingiva close to the apical foramen.
Study NCT03212729 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional endodontic treatment
Description: After local anesthesia the supragingival calculus, biofilm and the carious tissues were removed. The access cavity preparation was completed. The crown-down technique was performed using Gates Glidden and Kerr files with an anatomic diameter compatible to the radicular canal, and the irrigation was performed with 5 mL of 2.5% NaOCl solution between each endodontic file. The working length was established 1 mm short of the radiographic apex. Smear layer was removed by rinsing the canal with 17% ethylene diamine tetra-acetic acid solution, which was left in the canal for 5 min, followed by a final irrigation with 15 mL of 2.5% NaOCl solution. Calcium hydroxide paste with paramonoclorophenol, was inserted into the canal, filling the root canal as temporary medication between the sessions. The coronal sealing was performed using Coltosol, followed by glass ionomer Maxxion R. Seven days later the root canal was filled by the hybrid Tagger technique, with a Mc Spadden condenser.
Study NCT03212729 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional endodontic treatment
Description: After local anesthesia the supragingival calculus, biofilm and the carious tissues were removed. The access cavity preparation was completed. The crown-down technique was performed using Gates Glidden and Kerr files with an anatomic diameter compatible to the radicular canal, and the irrigation was performed with 5 mL of 2.5% NaOCl solution between each endodontic file. The working length was established 1 mm short of the radiographic apex. Smear layer was removed by rinsing the canal with 17% ethylene diamine tetra-acetic acid solution, which was left in the canal for 5 min, followed by a final irrigation with 15 mL of 2.5% NaOCl solution. Calcium hydroxide paste with paramonoclorophenol, was inserted into the canal, filling the root canal as temporary medication between the sessions. The coronal sealing was performed using Coltosol, followed by glass ionomer Maxxion R. Seven days later the root canal was filled by the hybrid Tagger technique, with a Mc Spadden condenser.
Study NCT03260712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: The dose of pembrolizumab in this trial is 200 mg Q3W.
Study NCT03260712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 25mg/m2 cisplatin on days 1 and 8 of a 21 day cycle
Study NCT03260712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000mg/m2 gemcitabine on days 1 and 8 of a 21 day cycle
Study NCT00138684 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: venesection
Description: Venesection therapy is realised every 7 - 14 days until iron desaturation completion.
Study NCT04243148 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Home exercise program for 12 months.
Description: Physical exercise at home: At the beginning of the study, group sessions will be conducted with 5 patients of 1-hour duration, where they will be taught the individualized program according to their physical condition and they will be given the necessary material (pedaling, dumbbells and elastic bands) and paper support on the program, also using the Vivifrail method through infographics. The group session will be repeated every 3 months to check the compliance of the program by reviewing daily activity, evaluate possible problems and review the exercises. The program will consist of aerobic and anaerobic exercise by pedaling (cardiovascular resistance) and resistance exercises with dumbbells and elastic bands (muscular strength), flexibility training by stretching, and coordination and balance exercises. Patients will perform 3 sessions per week of 20-30 min. increasing progressively according to tolerance up to 45-60 min. each.
Study NCT04243148 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Multispecies probiotic: Vivomixx®
Description: Multispecies probiotic: Vivomixx® is a probiotic mixture of 8 bacterial strains:~Streptococcus thermophilus DSM 24731® / NCIMB 30438, Bifidobacterium breve DSM 24732® / NCIMB 30441, Bifidobacterium longum DSM 24736® / NCIMB 30435\*, Bifidobacterium infantis DSM 24737® / NCIMB 30436\*, Lactobacillus acidophilus DSM 24735® / NCIMB 30442, Lactobacillus plantarum DSM 24730® / NCIMB 30437, Lactobacillus paracasei DSM 24733® / NCIMB 30439, Lactobacillus delbrueckii subsp. bulgaricus DSM 24734® / NCIMB 30440\*\*~\* Re-classified as B. lactis \*\* Re-classified as L. helveticus The active agent will be supplied as an envelope of 4.4 g with a dose of 450x109 million live bacteria per envelope with maltose and silicon dioxide as excipients, administered 2 times/day throughout the study.
Study NCT04243148 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Branched-chain amino acids (BCAA)
Description: Branched-chain amino acids (BCAA): In addition to the exercise program and the probiotic, patients in the intervention group will receive BCAA supplements (powder in 8:1:1 ratio in favor of L-leucine) 10 g 30-60 min. before the exercise session throughout the study, in order to enhance the effect of exercise on muscle mass and improve cognitive function. We have chosen this dose based on the literature data and the satisfactory results obtained with this dose in our previous study. BCAA supplements will be supplied by the Pharmacy Service of our center.
Study NCT04243148 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: No specific intervention.
Description: Follow up as a clinical practice
Study NCT00650507 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Description: The RIPC stimulus will be delivered in the OR prep room after the induction of anesthesia (while the anesthesiologist and staff are inserting vascular cannulae and preparing the patient for surgery). Whenever possible, the left lower limb will be selected for delivery of the stimulus. An appropriate sized cuff will be selected and connected to a hand aneroid sphygmomanometer. A second cuff and hand aneroid sphygmomanometer will be placed beside the one connected to the study subject. The cuff on the limb will be inflated and deflated to provide a total of four cycles of limb ischemia and reperfusion.
Study NCT00650507 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SHAM
Description: For this group, the procedure will be identical for that described for the RIPC stimulus, with the exception that the blood pressure cuff placed on the subject will not be inflated, but the second cuff, that has been placed beside, will be inflated.
Study NCT01474109 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: macitentan 3mg
Description: macitentan 3mg tablet once daily
Study NCT01474109 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: macitentan 10mg
Description: macitentan 10mg tablet once daily
Study NCT01474109 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo once daily
Study NCT01429688 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anplag
Description: Sarpogrelate HCl 300mg once a day or 100mg three times a day for 3 days
Study NCT02539446 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: stable condition
Study NCT02539446 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: unstable condition
Study NCT02539446 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: attentional focus
Study NCT02905812 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: RGI & Massage
Description: A trained intervention nurse will administer a 15 min moderate pressure massage as well as guided imagery with music once daily for up to five consecutive days.
Study NCT03379935 — intervention group
Intervention type: PROCEDURE
Intervention: Type of radial head arthroplasty
Description: Patiens are either treated with a unipolar or a bipolar radial head arthroplasty. At Sundsvall hospital all patients were treated with a unipolar and at Umeå university hospital all patients were treated with a bipolar arthroplasty.
Study NCT00917865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti [18F]FACBC
Description: Anti\[18F\]FACBC (10mci) will be given intravenously over 1-2 minutes prior to obtaining PET-CT images At 4 minutes, 10 consecutive/4minutes images will be obtained of the pelvis to include the prostate.
Study NCT04201041 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pudendal nerve pulsed radiofrequency
Description: received pudendal nerve pulsed radiofrequency through trans-vaginal approach or trans-gluteal approach
Study NCT01501188 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio Taping
Description: The participants were randomly assigned to an experimental group, to received Kinesio Taping application for gastrocnemius muscle enhancement and functional correction of the ankle.The treatment was performed three times a week during a 4-week period.
Study NCT01501188 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo kinesio taping
Description: Placebo-control group received treatment with a sham Kinesio Taping protocol to enhance gastrocnemius muscle function and dorsal ankle flexion.The strips used in this group did not follow the principles of tension and anatomic distribution of Kinesio technique.The treatment was performed three times a week during a 4-week period
Study NCT02323529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitisinone
Description: All patients in the study will first be put on twice daily dosing of nitisinone for 4 weeks. This will then be followed by once daily dosing of nitisinone for 4 weeks. The dose of nitisinone in the study will be the same as the one prescribed at completed screening visit. Dose will be 1-2 mg/kg body weight.
Study NCT00600548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miltefosine.
Description: Miltefosine: Capsules containing 10 mg or 50 mg miltefosine; administered orally for 28 days at dosage of 2.5 mg/kg body weight per day.
Study NCT00600548 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meglumine antimoniate.
Description: Meglumine antimoniate administered by intravenous route for 20 days at the dosage of 20mg/kg/day.
Study NCT04705623 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Iyengar Yoga
Description: Weekly 90 minute Iyengar Yoga classes taught y a professional instructor. Twice weekly 45 minute self practice of Iyengar Yoga at home by the participants
Study NCT02627183 — intervention group
Intervention type: PROCEDURE
Intervention: Catheter ablation
Description: Subjects undergoing catheter ablation for the first time for atrial fibrillation as part of their regular care (regardless of involvement in this study).
Study NCT02627183 — intervention group
Intervention type: BEHAVIORAL
Intervention: Exercise training
Description: Subjects participating in supervised exercise classes for up to 60 minutes in length 2 times/week as part of their involvement in another study (NCT02602457).
Study NCT00375453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SH U04722
Study NCT04408898 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ADP-A2M4 in combination with pembrolizumab.
Description: Single infusion of autologous genetically modified ADP-A2M4 Dose: 1.0 x109 to 10x109 transduced cells by a single intravenous infusion Repeat doses of pembrolizumab every 3 weeks. Dose: 200mg
Study NCT02806557 — intervention group
Intervention type: DEVICE
Intervention: Home finger-prick capillary blood count monitoring
Description: A nurse will visit the participant's home according to the test schedule (up to a maximum frequency of 21 visits in a 21-day cycle) and perform the finger-prick capillary blood test and measure the neutrophil count using the Hemocue® WBC DIFF device.
Study NCT02202499 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: All participants will take the following dose of varenicline: 0.5 mg once a day on days 1-3, 0.5 mg twice a day on days 4-7, and 1 mg twice a day through week 16 of the study. Arm descriptions show specific details for each group.
Study NCT02202499 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Counseling and Support Materials
Description: Counseling and support materials (including a review and self-monitoring workbook tentatively titled, Winding Down: A Guide to Quitting Smoking using Varenicline) instructing participants to systematically utilize the FE techniques provided.
Study NCT02202499 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Assessments
Description: The first laboratory assessment will consist of completion of questionnaires and a cue-reactivity test. The second laboratory assessment will be scheduled for the end of the week before the participant's quit date. It will involve completion of questionnaires and another cue reactivity test. A follow-up session conducted by research staff will occur one month after the target quit date to collect information about each participant's current smoking status, smoking rate, varenicline use, and opinion about the treatment. A second follow-up session will be conducted by telephone and will occur three months after the target quit date, at the end of varenicline use. At the end of the study, participants will be asked to complete a brief survey asking basic information, similar to the questions during the screening period.
Study NCT01490086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RP5063
Description: daily
Study NCT01490086 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: daily
Study NCT01490086 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aripiprazole
Description: daily
Study NCT03916835 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Pain evaluation ( FLACC scale) before and during the cleaning care with and without music therapy.
Description: Each child will benefit two cleaning cares during hospitalization. One with music therapy and the other without music therapy.~Every time, the preparation will be the same with an equipment installation in order to keep comparability and blind.~Child will be videotaped without sound during the care. The order of music therapy intervention will be randomized.